Symetis
Financials
Estimates*
EUR | 2015 | 2016 | 2017 | 2018 |
---|---|---|---|---|
Revenues | 4.6m | 4.7m | 4.3m | 4.4m |
% growth | - | 1 % | (8 %) | 4 % |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$9.6m | Series A | ||
$21.3m | Series B | ||
$25.8m | Series C | ||
N/A | Late VC | ||
N/A | Series D | ||
* | €396m Valuation: €396m 84.8x EV/LTM Revenues | Acquisition | |
Total Funding | €51.5m |
Recent News about Symetis
EditSymetis is a pioneering company in the medical technology sector, specializing in innovative solutions that enhance patient care. The company operates in the healthcare market, focusing on cardiovascular, gastroenterology, and urology specialties. Symetis serves a diverse range of clients, including hospitals, clinics, and medical professionals who require advanced medical devices to improve patient outcomes. The business model revolves around the development, manufacturing, and sale of high-quality medical devices such as single-use duodenoscopes, pacemakers, defibrillators, and stents. Revenue is generated through direct sales to healthcare providers and partnerships with medical institutions. Symetis is committed to sustainability and corporate social responsibility, ensuring that their operations positively impact communities worldwide.
Keywords: medical technology, cardiovascular devices, gastroenterology, urology, single-use duodenoscope, pacemakers, defibrillators, stents, patient care, healthcare innovation.